Open AccessEFFECT OF IMMUNOTHERAPY ON THE CELLULAR IMMUNITY IN PATIENTS WITH CERVICAL CANCER
Author(s) -
Lazarëv Af,
Kenbaeva Dk,
Medeubaev Rk,
Gorbatenko Ae,
Tanatarov Sz
Publication year - 2015
Publication title -
vestnik rossijskoj akademii medicinskih nauk
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.122
H-Index - 15
eISSN - 2414-3545
pISSN - 0869-6047
DOI - 10.15690/vramn.v69.i3-4.987
Subject(s) - immunotherapy , medicine , cervical cancer , immune system , context (archaeology) , cancer immunotherapy , immunology , cancer , radiation therapy , immunity , adoptive immunotherapy , cellular immunity , oncology , cancer research , biology , paleontology
For the last thirty years immunotherapy has become an integral part of treatment of some cancers. The most effective approach in this context would be the use of complex immunostimulatory factors including tumor antigen in different forms, interleukins that stimulate differentiation. Background: The aim of the study was to compare cellular immune response on specific and combined immunotherapy in patients with cervical cancer. Patients and methods: 76 cervical cancer patients undergoing combined radiotherapy were included into the study. Plus to basic radiation treatment two types of immunotherapy was performed: first — autolymphocytes reinfusion after in vitro incubation with tumor antigen (tumor tissue homogenate) and interleukin-2, second — combination of above mentioned immunotherapy, interleukin-2 and systemic enzyme. Results: This has resulted in increase of cellular immunity parameters in the main group with combined immunotherapy an excess of cells with killer activity to ensure an effective anti-tumor immune response and, accordingly, the clinical efficacy of specific methods and adoptive immunotherapy in patients with cervical cancer. Conclusion: Immunotherapy usage in the form of a preparation of interleukin-2 and a system enzymotherapy in a combination with a specific immunotherapy is possible. This way of treatment is recommended in cases of decreasing of cellular immunity indicators.